Quantcast

Latest Daunorubicin Stories

2009-03-26 07:00:00

PRINCETON, N.J., March 26 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, has accepted an invitation to present at the Future Leaders in the Biotech Industry conference in New York. Mr.

2009-03-10 07:00:00

The study is supported by The Leukemia & Lymphoma Society(R) PRINCETON, N.J., March 10 /PRNewswire/ -- Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients (up to 60 years old) with acute myeloid leukemia in first relapse.

2009-01-23 09:41:54

Researchers at the Johns Hopkins University School of Medicine have discovered how a whole class of commonly used chemotherapy drugs can block cancer growth.

2009-01-22 07:00:00

WHITE PLAINS, N.Y. and PRINCETON, N.J., Jan. 22 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc.

2009-01-08 11:38:00

PRINCETON, N.J., Jan. 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Biotech Showcase 2009 in San Francisco. Mr.

2008-12-09 07:00:00

Findings confirm advantages of fixed-ratio drug delivery and lay the groundwork for Phase 2 trials already underway in first-line and first-relapse Acute Myeloid Leukemia (AML) settings PRINCETON, N.J., Dec.

2008-09-23 12:00:52

Vion Pharmaceuticals, which develops and commercializes cancer therapeutics, has signed an agreement with the Institut Paoli-Calmettes in Marseille, France to conduct a multi-center Phase I/II clinical trial of laromustine with remission-induction therapy in patients aged 18-60 with previously untreated acute myelogenous leukemia and a poor prognosis based on their cytogenetic profile.

2008-09-05 03:00:27

Celator Pharmaceuticals has announced that the FDA has granted orphan drug designation to CPX-351 liposome injection for the treatment of acute myeloid leukemia. Celator is currently preparing to conduct two randomized Phase II studies with CPX-351.

2008-07-29 12:01:25

Celator Pharmaceuticals, which develops novel products based on proven combinations of chemotherapeutic drugs, has raised in excess of $22.5 million in a series C private equity financing.

2008-07-28 18:00:42

PRINCETON, N.J., July 28 /PRNewswire-FirstCall/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing novel products based on proven combinations of chemotherapeutic drugs, today announced that it raised in excess of $22.5 million in a Series C private equity financing.


Word of the Day
whirret
  • To give a box on the ear to.
The word 'whirret' may be onomatopoeic.